Lymphoma

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Recently, I met a fellow cancer survivor but after talking with her about cancer, I realized she had a different perspective than I did.

Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.

From Roger O’Donnell announcing his aggressive lymphoma diagnosis to “Love Is Blind’s” Shaina Hurley opening up about her cervical cancer while three months pregnant, here’s what’s happening in the oncology space this week.

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

Living with chronic small lymphocytic lymphoma for the past 15 years has taught me some very valuable lessons, from dieting to managing anxiety.

Treatment with Yescarta for B-cell lymphoma may be promising within the first five years, but the risk of secondary cancers may reduce survival long term.

Fatigue is a common side effect that may linger for years following cancer treatment. Experts and survivors talk about ways to help find a balance between life and fatigue.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

The militaristic terminology of “fighting a disease” does not sit well with me. After being diagnosed, I wasn’t fighting. I was reacting.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

One researcher explains the science behind Lymphir, recently approved by the FDA for relapsed/refractory cutaneous T-cell lymphoma.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

When I started experiencing symptoms of an infection, I was worried that my follicular lymphoma had returned.

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma.

From democratic Rep. Sheila Jackson Lee’s death from pancreatic cancer to the rock band, Widespread Panic, canceling shows due to their guitarist’s diagnosis, here’s what’s happening in the oncology space this week.

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Reduced doses of radiation were shown to be effective for some patients with indolent orbital B-cell lymphoma, researchers said.

After having SLL for 15 years, I won't let it define me — now, I'm working towards larger passions in my life.

After fully recovering from non-Hodgkin lymphoma, I’m ready to embark on my next chapter in life doing the things I love with the people I love.

I was told that after five years in remission, my cancer would be behind me. However, I was not told what life would be like after that milestone.

Having a check-up appointment without receiving any type of scan is good, but also scares me.

From the lead singer of Heart’s cancer diagnosis and postponing their tour to Dick Vitale’s upcoming cancer surgery, here’s what’s going on in the cancer space this week.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

Sometimes, laughter really is the best medicine, so I tried to maintain a sense of humor through my cancer treatments.

Although there are still cancer drugs in short supply, the chief medical officer at the NCCN explained that most patients will not get suboptimal care.

From Judge Frank Caprio opening up about his diagnosis of pancreatic cancer and treatment to an “Ink Master” star dying from testicular cancer, here’s what’s going on in the oncology space this week.

The Food and Drug Administration approved Epkinly, a bispecific T-cell engager, for certain patients with follicular lymphoma.

In children with T-lymphoblastic lymphoma, having an MRD status of less than 0.1% may lead to more time without their cancer worsening or coming back.